# Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study

> **NCT06598527** · PHASE3 · RECRUITING · sponsor: **Yang Hong** · enrollment: 360 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **RADIATION:** Stereotactic body radiotherapy (SBRT)
- **DRUG:** Tislelizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06598527
- **Lead sponsor:** Yang Hong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2027-01-30
- **Final completion:** 2030-01-30
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598527, "Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06598527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*